We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Arabinoxylan-Oligosaccharides Compared to Other Prebiotics in Healthy Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00853034
First Posted: February 27, 2009
Last Update Posted: February 27, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Katholieke Universiteit Leuven
  Purpose
The purpose of the study is to evaluate the effects of arabinoxylan-oligosaccharides (AXOS) on the colonic metabolism and microbial composition, and to compare these effects with the reference prebiotic fructo-oligosaccharide enriched inulin.

Condition Intervention Phase
Healthy Dietary Supplement: FOS-IN Dietary Supplement: AXOS Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Effects of Arabinoxylan-Oligosaccharides on Colonic Metabolism and Microbial Composition Compared to Other Prebiotics in Healthy Subjects

Further study details as provided by Katholieke Universiteit Leuven:

Enrollment: 20
Study Start Date: October 2006
Study Completion Date: September 2007
Arms Assigned Interventions
Active Comparator: FOS-IN
prebiotic fructo-oligosaccharide enriched inulin
Dietary Supplement: FOS-IN

prebiotic fructo-oligosaccharide enriched inulin

intake period: 2 weeks, 1.25 or 2.50g every morning and evening

Other Name: Synergy1, Orafti, Tienen
Experimental: AXOS
arabinoxylan-oligosaccharides (AXOS)
Dietary Supplement: AXOS

arabinoxylan-oligosaccharides (AXOS)

intake period: 2 weeks, 1.25 or 2.50g every morning and evening


  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy
  • 18-45 years
  • regular eating pattern

Exclusion Criteria:

  • gastrointestinal complaints
  • antibiotic intake
  • medication influencing gut transit or microbiota
  • abdominal surgery
  • pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00853034


Locations
Belgium
Department of Gastrointestinal Research, Laboratory Digestion and Absorption
Leuven, Belgium, 3000
Sponsors and Collaborators
Katholieke Universiteit Leuven
Investigators
Study Director: Kristin Verbeke, PhD Katholieke Universiteit Leuven
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00853034     History of Changes
Other Study ID Numbers: AXOS 001
First Submitted: February 25, 2009
First Posted: February 27, 2009
Last Update Posted: February 27, 2009
Last Verified: February 2009

Keywords provided by Katholieke Universiteit Leuven:
gastrointestinal effects
prebiotic